Abstract
Carbohydrates are important components of foods and essential biomolecules performing various biological functions in living systems. A variety of biological activities besides providing fuel have been explored and reported for carbohydrates. Some carbohydrates have been approved for the treatment of various diseases; however, carbohydrate-containing drugs represent only a small portion of all of the drugs on the market. This review summarizes several potential development directions of carbohydrate-containing therapeutics, with the hope of promoting the application of carbohydrates in drug development.
Introduction
Carbohydrates are ubiquitously present in a wide range of plants, animals, and microorganisms. Their irreplaceable biological roles have been well established. To date, a large number of carbohydrate-containing drugs have been approved worldwide (). However, the development of carbohydrate-containing drugs seems to have slowed down in recent years. Of more than 200 drugs that have been approved during 2015–2020, only nine are small-molecule carbohydrate-containing drugs (). This mini-review provides a summary and our opinion on the future of carbohydrate-containing drugs. Carbohydrates have three typical characteristics: high density of functional groups (e.g., hydroxyl), diversity of structures based on different configuration, and ideal biocompatibility as they are ubiquitous in the body. It is crucial to harness the intrinsic properties of carbohydrates in order to develop carbohydrate-containing therapeutics. Overall, five potential directions need to be focused on, namely, pure carbohydrate drugs, carbohydrate conjugates, carbohydrate scaffolds, carbohydrates vaccines, and glyconanomaterials (Figure 1).
FIGURE 1
Pure Carbohydrate Drugs
Carbohydrates present many advantages in drug screening, such as low cost, abundance, high density of functional groups, and diversity of molecular structures. However, in clinical practice, it is rare to directly use carbohydrates as drugs or carbohydrates as the main body of drugs. Monosaccharides are ubiquitous in our body, and thus, they are difficult to directly use as drugs. However, some decorated monosaccharides have been approved for the treatment of specific diseases by mimicking functions of monosaccharides. 18F-fluorodeoxyglucose (18F-FDG) injection is a typical example (Figure 2). 18F-FDG is a radioactive 2-deoxy-2-[18F] fluoro-d-glucose that has been used for the diagnosis of cancer in conjunction with positron emission tomography (). Based on the fact that cancerous tissues take up glucose at a higher rate than most normal tissues, 18F-FDG is preferentially uptaken by tumor cells, thus allowing clinicians to identify sites of tumors and metastases, as well as to stage cancer and monitor response to treatment.
FIGURE 2
Oligosaccharides and polysaccharides show low lipophilicity due to the presence of multiple hydroxyl groups. Typically, the less lipophilic a drug, the worse is its absorption following oral administration (). Therefore, they are usually designed for the treatment of the gastrointestinal tract diseases, where less absorption is acceptable or necessary. Lactulose (Figure 3), a disaccharide, is a typical example, which undergoes minimal gastrointestinal tract absorption and being broken into organic acids by saccharolytic bacteria and thus enhances intraluminal gas formation and facilitates bowel movements. Therefore, it has been used for the treatment of chronic constipation (). In addition, intravenous administration is also an option for this type of therapeutic agent with high polarity. Heparin (Figure 3) is a sulfated polysaccharide isolated from animal organs, and it has been used clinically as an intravenously injected antithrombotic agent for decades (). However, it is a highly heterogeneous mixture of polysaccharides and is associated with severe side effects. After the structure–function relationship of heparin was established using synthetic oligosaccharides, some antithrombotic agents with definite single structures were developed, such as fondaparinux and idraparinux (Figure 3) (; ). Idraparinux is a fully synthetic analog of the pentasaccharidic domain of heparin, which contains O-sulfation and O-methyl functionalities instead of N-sulfation and free hydroxyl groups. It has a chemically defined structure, and it is also an analog of fondaparinux. Compared with fondaparinux, idraparinux shows a higher anti-Xa activity and longer half-life, and it has been in a phase III clinical trial for the treatment of patients with atrial fibrillation and venous thromboembolic events. Recently, a seaweed-derived oligosaccharide, GV-971, has been approved in China for the treatment of Alzheimer disease (). GV-971 is a heterogeneous mixture of acidic linear oligosaccharides ranging from dimers to decamers. A study recently published by Geng et al. showed that GV-971 could decrease Aβ-related pathologies by reconditioning the gut microbiota. With the establishment of the structure–function relationship of GV971, oligosaccharides with definite single structures may open new possibilities in the therapeutic field of Alzheimer disease.
FIGURE 3
Carbohydrate Conjugates
Carbohydrate conjugates refer to carbohydrates that are used in the attachment of drugs. In this case, the carbohydrate molecule itself is not the main body of drugs; rather, it is a functional group utilized to increase their bioactivity, improve physical and chemical properties, or achieve targeting. The vast majority of the drugs containing carbohydrates that are already on the market fall into this category. This is not surprising, given that the high polarity and multifunctional properties of carbohydrates make them ideal additions to improve drug properties. However, it is noteworthy that either these approved drugs have originated from natural products containing carbohydrate molecules (e.g., antibiotics and vancomycin; Figure 4A), or they have been designed based on the key components containing carbohydrates in the body (e.g., nucleoside analogs and cytarabine; Figure 4B) (; ). Apart from these two aspects, carbohydrates have much more potential for exploitation in drug design. For example, a number of carbohydrate-containing probes with potential diagnostic applications have been reported (e.g., KSL11; Figure 4C); they could be used to detect ions, small molecules, and enzymes (; ; ; ). Furthermore, carbohydrates (glucose or other glucose transporter substrates) have been conjugated to cytotoxins or anticancer therapeutics for the specific targeting and treatment of cancer (). The rationale behind this strategy is that glucose transporters and glycolytic enzymes are widely overexpressed in cancer tissues, which highly correlates with poor cancer prognosis, thus making them attractive therapeutic targets for achieving anticancer drug targeting (). The wide application of 18F-FDG injection in diagnosis and staging of many types of cancer provides the strongest support to this theory. Cancers clinically staged using 18F-FDG imaging may be good candidates for glycoconjugate targeting. According to Bensinger et al., they include lung, breast, colorectal, and endometrial carcinomas, as well as bone and soft tissue sarcomas and Hodgkin and non-Hodgkin lymphomas (). Actually, carbohydrate-conjugated anticancer active molecules for targeting therapy have attracted great interest and grown markedly in recent years. Several clinical trials in several countries over the past decades have been conducted on glufosfamide, a trailblazer for glycoconjugated anticancer agents (; ). In addition, some glycoconjugates have shown improved activity and selectivity compared with aglycone in vitro and in vivo (e.g., glucose–platinum conjugate; Figure 4D) (; ; ; ; ). However, this drug design strategy has not yet been proven in clinical practice, which somewhat undermines the confidence of researchers in the field. The questions remain as to how to choose the proper coupling position of carbohydrate, what is the exact mechanism of glycoconjugates entry into cells, and how glycoconjugates work in vivo.
FIGURE 4
Carbohydrate as Scaffolds
Carbohydrates have high functional group density and diversity of functional group orientations, which makes them excellent scaffolds for designing bioactive compounds by appending desired substituents at selected positions around the sugar ring. This strategy has promising prospects in drug development, and it has widely been used in the design of peptidomimetics. It is known that the instability of the amide backbone is an important limiting factor in the development of peptide drugs. In addition, the amide backbone makes the peptides less permeable to membranes, which leads to their lower bioavailability. Accordingly, using carbohydrates to mimic the backbone of peptides is a promising strategy for increasing the drug ability of peptides. Since Hirschmann et al. first reported that the peptidomimetic based on β-d-glucoside scaffold (Figure 5A) could target somatostatin receptor, several research groups have reported the various applications of peptidomimetics based on carbohydrate scaffolds in different biological fields (; ). Relevant studies of peptidomimetics have been reviewed extensively elsewhere (; ; ; ; ; ). However, the existing examples have also demonstrated the difficulty of designing single carbohydrate scaffold mimetics that maintain the level of bioactivity (and/or selectivity) of the counterparts. This is because it is difficult to ensure that the positions and orientations of the functional groups of the mimetics are exactly the same as those of the counterparts (original ligands). A possible solution is to use carbohydrates as scaffolds to build a diverse library of compounds and to use the library to screen the ideal molecules (; ; ). The novel strategy has been used to screen inhibitors of protein tyrosine phosphatase 1B (PTP1B) in our group, where ribose and xylose were used as scaffold (Figure 5B) (). The successful obtainment of a potent and selective PTP1B inhibitor preliminarily proved the feasibility of this strategy. However, in the current research, carbohydrate scaffolds were modified with the same pharmacophore in one molecule, which did reduce the difficulty of the reaction, but also dramatically reduced the diversity of compounds. Presenting different pharmacophores at different substitution sites of the carbohydrate scaffold can greatly increase the diversity of compounds. Thus, based on this research idea, efficient organic synthesis methods that involve the individual sequential protection and deprotection of single hydroxyl group on sugar rings are essential. Advances in organic synthesis in the field of carbohydrate chemistry have accelerated and extended the application of this strategy (; ). It is expected that as the power of organic synthesis increases, it will be an alternative for drug development to utilize carbohydrates as scaffolds to generate compound libraries that are highly functional and structurally diverse and to further screen bioactive molecules.
FIGURE 5
Carbohydrates Used for Vaccines
Carbohydrates have also been used for the development of vaccines, such as carbohydrate-based antimicrobial vaccines and anticancer vaccines (). The star drug Prevnar 13 is a typical polysaccharide–protein conjugate vaccine; it was approved by the US Food and Drug Administration in 2010 (). The rationale behind carbohydrate-based vaccines is based on the theory that carbohydrates could be recognized as antigenic determinants, and they could be specifically recognized by the immune system (). Capsular polysaccharides and lipopolysaccharides are the major constituents of the microbial cell surfaces and can be specifically recognized by the host immune system; thus, they could be exploited as the basis for the design of antibacterial vaccines. Expression of carbohydrates on the cancer cell surface is different from that on the normal cell surface. Abnormal glycosylation in primary tumors closely correlates with the survival rate of cancer patients. These abnormal oligosaccharides or polysaccharides, usually referred to as tumor-associated carbohydrate antigens, are strictly related to the metastasis of tumor cells. Based on the immunogenicity of carbohydrates, the development of carbohydrate-based vaccines provides an attractive option for the treatment of infections and cancers. The main difficulty in carbohydrate vaccine development is the poor immunogenicity due to their inherent T-cell–independent nature. In the response to this class of carbohydrate antigens, no immunological memory is established, and no T-cell responses are induced, which is markedly different from responses to proteins and peptides. One method of overcoming this problem is to conjugate the corresponding carbohydrates to a carrier protein (). However, we need to solve first how to obtain carbohydrate antigens with sufficient quantity, high purity, and structural integrity. In addition, natural polysaccharides obtained by separation are usually characterized by significant heterogeneity and easy contamination. Several studies have demonstrated that synthetic conjugates show comparable activity to the native polysaccharides linked to the same carrier protein, indicating that the chemically well-defined synthetic oligosaccharide is safer than the natural polysaccharide counterpart. Moreover, fully synthetic oligosaccharide conjugate vaccines have more advantages because they could be designed to incorporate only elements required for a desired immune response, and they could produce chemically well-defined compounds in a reproducible fashion. Therefore, efficient synthetic methods are critical for the development of carbohydrate-based vaccines. Although the construction of oligosaccharides remains a challenging task due to the combined demands of elaborate procedures for glycosyl donor and acceptor preparation and the requirements of regio- and stereo-selectivity in glycoside bond formation, considerable improvements have been made in this field (; ; ). It is expected that new and efficient synthetic methods will be developed in the near future, which will give access to a wide range of oligosaccharides and glycoconjugates for vaccine development.
Glyconanomaterials
Carbohydrates have been conjugated to nanomaterials for biomedical imaging, diagnostics, and therapeutics (; ). In addition, some carbohydrate-containing drugs have been used in nanodelivery systems as cargos for enhancing drug efficacy, reducing nonspecific toxicity or improving targeting (; ). The combination of glycochemobiology and nanotechnology has provided promising new tools that could be used in imaging of cancer cells, photodynamic therapy, biosensors, and drug targeting (). In this section, the application of carbohydrates in the modification of nanomaterials is highlighted. Considering their ubiquitous distribution in tissues and important functions at the cellular level, carbohydrates have been widely used in the functionalization of nanomaterials and have shown unique advantages in the development of nanomedicines. Strategies for the design, preparation, and application of glyconanomaterials have been summarized in many recent reviews (; ; ; ; ). Generally, carbohydrates have three typical advantages in the development of nanomedicine. In addition to increasing water solubility, the main advantages are improving the biocompatibility of nanomaterial and facilitating the improvement of affinity for receptors. In terms of biocompatibility, carbohydrates are an ideal choice to overcome nanomaterial immunogenicity that has limited the use of nanomaterials in vivo to a large extent. The rationale behind this advantage is that host-like glycan structures in a form of molecular mimicry could assist some pathogens to evade recognition from the host immune system (). Thus, it is not surprising that carbohydrate-decorated nanoparticles have lower immunogenicity compared with unmodified nanomaterials. As a major nonimmunogenic carbohydrate component, glucose has been used in the design of glyconanoparticles in the study by . In terms of increasing affinity, the synergy between nanomaterials and carbohydrates showed huge potential advantages. Nanomaterials, a kind of formidable platform, could make the presentation of multiple carbohydrate ligands possible via the large surface-to-volume ratio, thereby greatly increasing the affinity of carbohydrates as biofunctional ligands for specific glycan-binding proteins. The study by Reynolds et al. showed that the gold nanoparticle platform displayed a significant cluster glycoside effect for presenting carbohydrate ligands with almost a 3,000-fold increase in binding compared with a monovalent reference probe in free solution (). The targeting aggregation capacity of carbohydrates has further been demonstrated in the study of nanocarrier-mediated drug delivery into the brain (). According to Anraku et al., the nanocarrier with a surface featuring many glucose molecules has the potential for delivering various drugs directly into the brain by crossing the blood–brain barrier (BBB) through taking advantage of a multivalent interaction between multiple glucose molecules and glucose transporters (Figure 6) (). Further, carbohydrate-decorated nanoparticles could be used as the active therapeutic entities to inhibit pathogen adhesion—the first step to initiate infection. A study showed that 120 monosaccharides that functionalized tridecafullerene exhibited a potent inhibitory effect against cell infection caused by an artificial Ebola virus with half-maximum inhibitory concentrations in the subnanomolar range (). More recently, Bhatia et al. reported adaptive flexible sialylated nanogels that could deform and adapt onto the influenza A virus surface via multivalent binding of sialic acid residues with hemagglutinin spike proteins on the virus surface. Based on the multivalent binding strategy, sialylated nanogels could efficiently block the virus adhesion on cells and inhibit the infection at low pM concentrations ().
FIGURE 6
As for carbohydrate-decorated nanomaterials, the key aspects of their performance include the proper display of carbohydrate ligands, the type and length of the spacer linkage, and the ligand density. Receptors have the best affinity for specific carbohydrate molecules; for example, glucose transporter-1 shows higher affinity to glucose compared with other monosaccharides; therefore, the selection of carbohydrate molecules is crucial in the functionalization of nanomaterials. In addition, the effect of linkers on the binding affinity of glyconanoparticles has also been investigated in recent studies (; ; ; ). The results showed that the binding affinity increased with the spacer linker length. The longer and more flexible spacer may provide additional spatial freedom and less steric hindrance to the attached ligands for a more efficient association with their binding partners. Regarding the effect of carbohydrate ligand density, it is reasonable that carbohydrate molecules recognize receptors principally through weak interactions such as hydrogen bonding; thus, increasing the carbohydrate ligand density may introduce cluster or multivalency effects, which could significantly enhance the binding affinity. The most representative example is that oligosaccharides usually exhibit higher binding affinity than monosaccharides toward the same lectin receptor. Although the binding affinity could be roughly quantified by technical means already available, such as surface plasmon resonance or isothermal titration calorimetry, in general, it is difficult to control the number of carbohydrate ligands conjugated to relative nanomaterials. Such imprecise preparation methods may result in ambiguities in composition and structure and batch-wise variations of prepared glyconanomaterials, which is one of the important factors limiting carbohydrates’ clinical development.
Conclusion
Overall, the present review summarized the possible directions of carbohydrate-containing drugs based on the internal characteristics of carbohydrates. As the biological functions of carbohydrates continue to be explored and more novel carbohydrate-containing molecules are artificially designed or obtained from natural products, it is expected that carbohydrates as the treasure house of medicine will bring more surprises to us in the near future.
Statements
Author contributions
JW, YZ, and RZ conceived and designed the framework of this article. RZ wrote it. QL and DX are responsible for revising.
Funding
This work was supported by the Youth Innovation Team Talent Introduction Program of Shandong Province (20190164) and China Postdoctoral Science Foundation (2021T140355).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AnrakuY.KuwaharaH.FukusatoY.MizoguchiA.IshiiT.NittaK.et al (2017). Glycaemic Control Boosts Glucosylated Nanocarrier Crossing the BBB into the Brain. Nat. Commun.8 (1), 1001. 10.1038/s41467-017-00952-3
2
BaeS. H.KimM. R. (2020). Subtype Classification of Functional Constipation in Children: Polyethylene Glycol Versus Lactulose. Pediatr. Int.62 (7), 816–819. 10.1111/ped.14235
3
Ben-HaimS.EllP. (2009). 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response. J. Nucl. Med.50 (1), 88–99. 10.2967/jnumed.108.054205
4
BensingerS. J.ChristofkH. R. (2012). New Aspects of the Warburg Effect in Cancer Cell Biology. Semin. Cell Dev. Biol.23 (4), 352–361. 10.1016/j.semcdb.2012.02.003
5
BhatiaS.HilschM.Cuellar-CamachoJ. L.LudwigK.NieC.ParshadB.et al (2020). Adaptive Flexible Sialylated Nanogels as Highly Potent Influenza A Virus Inhibitors. Angew. Chem. Int. Ed. Engl.59, 12417–12422. 10.1002/anie.202006145
6
BhutaniP.JoshiG.RajaN.BachhavN.RajannaP. K.BhutaniH.et al (2021). U.S. FDA Approved Drugs from 2015-June 2020: A Perspective. J. Med. Chem.64 (5), 2339–2381. 10.1021/acs.jmedchem.0c01786
7
BriasoulisE.PavlidisN.TerretC.BauerJ.FiedlerW.SchöffskiP.et al (2003). Glufosfamide Administered Using a 1-hour Infusion Given as First-Line Treatment for Advanced Pancreatic Cancer. A Phase II Trial of the EORTC-New Drug Development Group. Eur. J. Cancer39 (16), 2334–2340. 10.1016/s0959-8049(03)00629-4
8
BuggT. D.BraddickD.DowsonC. G.RoperD. I. (2011). Bacterial Cell wall Assembly: Still an Attractive Antibacterial Target. Trends Biotechnol.29 (4), 167–173. 10.1016/j.tibtech.2010.12.006
9
BustoE. (2016). Recent Developments in the Preparation of Carbohydrate Derivatives from Achiral Building Blocks by Using Aldolases. ChemCatChem8 (16), 2589–2598. 10.1002/cctc.201600366
10
CalvaresiE. C.HergenrotherP. J. (2013). Glucose Conjugation for the Specific Targeting and Treatment of Cancer. Chem. Sci.4 (6), 2319–2333. 10.1039/c3sc22205e
11
CipollaL.La FerlaB.AiroldiC.ZonaC.OrsatoA.ShaikhN.et al (2010). Carbohydrate Mimetics and Scaffolds: Sweet Spots in Medicinal Chemistry. Future Med. Chem.2 (4), 587–599. 10.4155/fmc.10.8
12
CipollaL.PeriF.FerlaB.RedaelliC.NicotraF. (2005). Carbohydrate Scaffolds for the Production of Bioactive Compounds. Cos2 (2), 153–173. 10.2174/1570179053545341
13
CiuleanuT. E.PavlovskyA. V.BodokyG.GarinA. M.LangmuirV. K.KrollS.et al (2009). A Randomised Phase III Trial of Glufosfamide Compared with Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine. Eur. J. Cancer45 (9), 1589–1596. 10.1016/j.ejca.2008.12.022
14
CruchoC. I. C.BarrosM. T. (2019). Stimuli-Responsive Glyconanomaterials for Sensing Applications. Nanomater. Des. Sens. Appl.8, 257–279. 10.1016/B978-0-12-814505-0.00008-4
15
DelormeV.LichonL.MahindadH.HungerS.LarouiN.DauratM.et al (2020). Reverse Poly(ε-Caprolactone)-g-Dextran Graft Copolymers. Nano-Carriers for Intracellular Uptake of Anticancer Drugs. Carbohydr. Polym.232, 115764–115772. 10.1016/j.carbpol.2019.115764
16
DeyS.LoH. J.WongC. H. (2019). An Efficient Modular One-Pot Synthesis of Heparin-Based Anticoagulant Idraparinux. J. Am. Chem. Soc.141 (26), 10309–10314. 10.1021/jacs.9b03266
17
FrigellJ.GarcíaI.Gómez-VallejoV.LlopJ.PenadésS. (2013). 68Ga-Labeled Gold Glyconanoparticles for Exploring Blood-Brain Barrier Permeability: Preparation, Biodistribution Studies, and Improved Brain Uptake via Neuropeptide Conjugation. J. Am. Chem. Soc.136 (1), 449–457. 10.1021/ja411096m
18
GaliliU. (2020). Host Synthesized Carbohydrate Antigens on Viral Glycoproteins as “Achilles’ Heel” of Viruses Contributing to Anti-Viral Immune Protection. Int. J. Mol. Sci.21 (18), 6702. 10.3390/ijms21186702
19
GhoshB.KulkarniS. S. (2020). Advances in Protecting Groups for Oligosaccharide Synthesis. Chem. Asian J.15 (4), 450–462. 10.1002/asia.201901621
20
GorityalaB. K.MaJ.WangX.ChenP.LiuX. W. (2010). Carbohydrate Functionalized Carbon Nanotubes and Their Applications. Chem. Soc. Rev.39 (8), 2925–2934. 10.1039/b919525b
21
GruberW. C.ScottD. A.EminiE. A. (2012). Development and Clinical Evaluation of Prevnar 13, a 13-valent Pneumocococcal CRM197 Conjugate Vaccine. Ann. N. Y Acad. Sci.1263, 15–26. 10.1111/j.1749-6632.2012.06673.x
22
HaoN.NeranonK.RamströmO.YanM. (2016). Glyconanomaterials for Biosensing Applications. Biosens. Bioelectron.76, 113–130. 10.1016/j.bios.2015.07.031
23
HeJ.HuangH.ZouX.WangY.DuG.KangZ. (2020). Construction of Saturated Odd- and Even-Numbered Hyaluronan Oligosaccharide Building Block Library. Carbohydr. Polym.231, 115700–115706. 10.1016/j.carbpol.2019.115700
24
HirschmannR. F.NicolaouK. C.AngelesA. R.ChenJ. S.SmithA. B. (2009). The Beta-D-Glucose Scaffold as a Beta-Turn Mimetic. Acc. Chem. Res.42 (10), 1511–1520. 10.1021/ar900020x
25
HirschmannR.NicolaouK. C.PietranicoS.SalvinoJ.LeahyE. M.SprengelerP. A.et al (1992). Nonpeptidal Peptidomimetics with Beta-D-Glucose Scaffolding. A Partial Somatostatin Agonist Bearing a Close Structural Relationship to a Potent, Selective Substance P Antagonist. J. Am. Chem. Soc.114 (23), 9217–9218. 10.1021/ja00049a081
26
HollingsworthR. I.WangG. (2000). Toward a Carbohydrate-Based Chemistry: Progress in the Development of General-Purpose Chiral Synthons from Carbohydrates. Chem. Rev.100 (12), 4267–4282. 10.1021/cr990374e
27
JiangH.QinX.WangQ.XuQ.WangJ.WuY.et al (2021). Application of Carbohydrates in Approved Small Molecule Drugs: A Review. Eur. J. Med. Chem.223, 113633. 10.1016/j.ejmech.2021.113633
28
JordheimL. P.DurantelD.ZoulimF.DumontetC. (2013). Advances in the Development of Nucleoside and Nucleotide Analogues for Cancer and Viral Diseases. Nat. Rev. Drug Discov.12 (6), 447–464. 10.1038/nrd4010
29
KhanH.MirzaeiH. R.AmiriA.Kupeli AkkolE.Ashhad HalimiS. M.MirzaeiH. (2019). Glyco-nanoparticles: New Drug Delivery Systems in Cancer Therapy. Semin. Cancer Biol.69, 24–42. 10.1016/j.semcancer.2019.12.004
30
LeG. T.AbbenanteG.BeckerB.GrathwohlM.HallidayJ.TometzkiG.et al (2003). Molecular Diversity Through Sugar Scaffolds. Drug Discov. Today8 (15), 701–709. 10.1016/s1359-6446(03)02751-x
31
LenciE.MenchiG.TrabocchiA. (2016). Carbohydrates in Diversity-Oriented Synthesis: Challenges and Opportunities. Org. Biomol. Chem.14 (3), 808–825. 10.1039/c5ob02253c
32
LenciE.TrabocchiA. (2020). Peptidomimetic Toolbox for Drug Discovery. Chem. Soc. Rev.49 (11), 3262–3277. 10.1039/d0cs00102c
33
LiL.FangZ. (2015). A Novel “Turn On” Glucose-Based Rhodamine B Fluorescent Chemosensor for Mercury Ions Recognition in Aqueous Solution. Spectrosc. Lett.48, 578–585. 10.1080/00387010.2014.933354
34
LiX.QiuW.LiJ.ChenX.HuY.GaoY.et al (2020). First-Generation Species-Selective Chemical Probes for Fluorescence Imaging of Human Senescence-Associated β-galactosidase. Chem. Sci.11 (28), 7292–7301. 10.1039/D0SC01234C
35
LiY.WangH.LiJ.ZhengJ.XuX.YangR. (2011). Simultaneous Intracellular β-D-Glucosidase and Phosphodiesterase I Activities Measurements Based on a Triple-Signaling Fluorescent Probe. Anal. Chem.83 (4), 1268–1274. 10.1021/ac102095j
36
MalakootikhahJ.RezayanA. H.NegahdariB.NasseriS.RastegarH. (2017). Glucose Reinforced Fe3O4@cellulose Mediated Amino Acid: Reusable Magnetic Glyconanoparticles with Enhanced Bacteria Capture Efficiency. Carbohydr. Polym.170, 190–197. 10.1016/j.carbpol.2017.04.078
37
MarradiM.ChiodoF.GarcíaI.PenadésS. (2013). Glyconanoparticles as Multifunctional and Multimodal Carbohydrate Systems. Chem. Soc. Rev.42 (11), 4728–4745. 10.1039/c2cs35420a
38
MettuR.ChenC. Y.WuC. Y. (2020). Synthetic Carbohydrate-Based Vaccines: Challenges and Opportunities. J. Biomed. Sci.27 (1), 9. 10.1186/s12929-019-0591-0
39
MeutermansW.LeG. T.BeckerB. (2006). Carbohydrates as Scaffolds in Drug Discovery. ChemMedChem1 (11), 1164–1194. 10.1002/cmdc.200600150
40
MikuniK.NakanishiK.HaraK.HaraK.IwataniW.AmanoT.et al (2008). In Vivo antitumor Activity of Novel Water-Soluble Taxoids. Biol. Pharm. Bull.31 (6), 1155–1158. 10.1248/bpb.31.1155
41
Miot-NoiraultE.ReuxB.DebitonE.MadelmontJ. C.ChezalJ. M.CoudertP.et al (2011). Preclinical Investigation of Tolerance and Antitumour Activity of New Fluorodeoxyglucose-Coupled Chlorambucil Alkylating Agents. Invest. New Drugs29 (3), 424–433. 10.1007/s10637-009-9371-0
42
MuñozA.SigwaltD.IllescasB. M.LuczkowiakJ.Rodríguez-PérezL.NierengartenI.et al (2016). Synthesis of Giant Globular Multivalent Glycofullerenes as Potent Inhibitors in a Model of Ebola Virus Infection. Nat. Chem.8 (1), 50–57. 10.1038/nchem.2387
43
PatraM.JohnstoneT. C.SuntharalingamK.LippardS. J. (2016). A Potent Glucose-Platinum Conjugate Exploits Glucose Transporters and Preferentially Accumulates in Cancer Cells. Angew. Chem. Int. Ed. Engl.55 (7), 2550–2554. 10.1002/anie.201510551
44
QiuM.HuangS.LuoC.WuZ.LiangB.HuangH.et al (2021). Pharmacological and Clinical Application of Heparin Progress: An Essential Drug for Modern Medicine. Biomed. Pharmacother.139, 111561. 10.1016/j.biopha.2021.111561
45
ReichardtN. C.Martín-LomasM.PenadésS. (2016). Opportunities for Glyconanomaterials in Personalized Medicine. Chem. Commun.52 (92), 13430–13439. 10.1039/c6cc04445j
46
ReynoldsM.MarradiM.ImbertyA.PenadésS.PérezS. (2012). Multivalent Gold Glycoclusters: High Affinity Molecular Recognition by Bacterial Lectin PA-IL. Chemistry18 (14), 4264–4273. 10.1002/chem.201102034
47
RichardsS. J.JonesM. W.HunabanM.HaddletonD. M.GibsonM. I. (2012). Probing Bacterial-Toxin Inhibition with Synthetic Glycopolymers Prepared by Tandem Post-Polymerization Modification: Role of Linker Length and Carbohydrate Density. Angew. Chem. Int. Ed. Engl.51 (31), 7812–7816. 10.1002/anie.201202945
48
SenanayakeT. H.WarrenG.VinogradovS. V. (2011). Novel Anticancer Polymeric Conjugates of Activated Nucleoside Analogues. Bioconjug. Chem.22 (10), 1983–1993. 10.1021/bc200173e
49
SeveriE.HoodD. W.ThomasG. H. (2007). Sialic Acid Utilization by Bacterial Pathogens. Microbiology153 (9), 2817–2822. 10.1099/mic.0.2007/009480-0
50
SimpsonJ.CraigD.FauldsK.GrahamD. (2016). Mixed-monolayer Glyconanoparticles for the Detection of Cholera Toxin by Surface Enhanced Raman Spectroscopy. Nanoscale Horiz1 (1), 60–63. 10.1039/C5NH00036J
51
TemmeJ. S.ButlerD. L.GildersleeveJ. C. (2021). Anti-Glycan Antibodies: Roles in Human Disease. Biochem. J.478 (8), 1485–1509. 10.1042/BCJ20200610
52
TianG.-Z.WangX.-L.HuJ.WangX.-B.GuoX.-Q.YinJ. (2015). Recent Progress of Sugar Amino Acids: Synthetic Strategies and Applications as Glycomimetics and Peptidomimetics. Chin. Chem. Lett.26 (8), 922–930. 10.1016/j.cclet.2015.04.026
53
TreekoonJ.PewklangT.ChansaenpakK.GorantlaJ. N.PengthaisongS.LaiR.-Y.et al (2021). Glucose Conjugated Aza-BODIPY for Enhanced Photodynamic Cancer Therapy. Org. Biomol. Chem.19 (26), 5867–5875. 10.1039/d1ob00400j
54
VelterI.La FerlaB.NicotraF. (2006). Carbohydrate‐Based Molecular Scaffolding. J. Carbohydr. Chem.25 (2-3), 97–138. 10.1080/07328300600733020
55
WangX.RamströmO.YanM. (2010). Glyconanomaterials: Synthesis, Characterization, and Ligand Presentation. Adv. Mater.22 (17), 1946–1953. 10.1002/adma.200903908
56
WangX.SunG.FengT.ZhangJ.HuangX.WangT.et al (2019). Sodium Oligomannate Therapeutically Remodels Gut Microbiota and Suppresses Gut Bacterial Amino Acids-Shaped Neuroinflammation to Inhibit Alzheimer's Disease Progression. Cell Res29 (10), 787–803. 10.1038/s41422-019-0216-x
57
WangZ.XuZ.ZhuG. (2016). A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair to Overcome Cisplatin Resistance. Angew. Chem. Int. Ed. Engl.55 (50), 15564–15568. 10.1002/anie.201608936
58
WitczakZ. J. (2006). Carbohydrate Therapeutics: New Developments and Strategies. Carbohydr. Drug Des.2, 25–46. 10.1021/bk-2006-0932.ch002
59
YangY. K.ShimS.TaeJ. (2010). Rhodamine-sugar Based Turn-On Fluorescent Probe for the Detection of Cysteine and Homocysteine in Water. Chem. Commun.46 (41), 7766–7768. 10.1039/c0cc02381g
60
YılmazÇ.ÖzcengizG. (2017). Antibiotics: Pharmacokinetics, Toxicity, Resistance and Multidrug Efflux Pumps. Biochem. Pharmacol.133, 43–62. 10.1016/j.bcp.2016.10.005
61
ZhangR.SongL.JiangB.WangL.WuN.GuoS.et al (2017). Design of Antitumor Agents Containing Carbohydrate Based on GLUT1, and Evaluation of Antiproliferative Activity. Bioorg. Med. Chem. Lett.27 (11), 2488–2492. 10.1016/j.bmcl.2017.03.094
62
ZhangR.YuR.XuQ.LiX.LuoJ.JiangB.et al (2017). Discovery and Evaluation of the Hybrid of Bromophenol and Saccharide as Potent and Selective Protein Tyrosine Phosphatase 1B Inhibitors. Eur. J. Med. Chem.134, 24–33. 10.1016/j.ejmech.2017.04.004
63
ZhangX.HuangG.HuangH. (2018). The Glyconanoparticle as Carrier for Drug Delivery. Drug Deliv.25 (1), 1840–1845. 10.1080/10717544.2018.1519001
64
ZhuX.SchmidtR. R. (2009). New Principles for Glycoside-Bond Formation. Angew. Chem. Int. Ed. Engl.48 (11), 1900–1934. 10.1002/anie.200802036
Summary
Keywords
carbohydrate, drug discovery, drug design, conjugates, glyconanomaterials
Citation
Wang J, Zhang Y, Lu Q, Xing D and Zhang R (2021) Exploring Carbohydrates for Therapeutics: A Review on Future Directions. Front. Pharmacol. 12:756724. doi: 10.3389/fphar.2021.756724
Received
11 August 2021
Accepted
08 October 2021
Published
16 November 2021
Volume
12 - 2021
Edited by
Chiranjib Chakraborty, Adamas University, India
Reviewed by
Rama P. Tripathi, CSIR-Central Drug Research Institute, India
Jesus Jimenez-Barbero, CIC bioGUNE, Spain
Vinod Tiwari, Banaras Hindu University, India
Updates
Copyright
© 2021 Wang, Zhang, Lu, Xing and Zhang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Renshuai Zhang, zhangrenshuai@qdu.edu.cn
† These authors have contributed equally to this work
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.